Merck (NYSE: MRK) reported Q1 EPS of $1.40, $0.05 better than the analyst estimate of $1.35. Revenue for the quarter came in at $0 versus the consensus estimate of $13.78 billion.

GUIDANCE:

Merck sees FY2023 EPS of $6.88-$7.00, versus the consensus of $6.91. Merck sees FY2023 revenue of $57.7-58.9 billion, versus the consensus of $58.3 billion.

For earnings history and earnings-related data on Merck (MRK) click here.